Takeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025. In the quarter to June 2026, revenue grew 1.71%, EPS fell 4.35%, free cash flow fell 95.6% and total debt fell 2.58%, each against the same quarter a year earlier.
Follow TAK
Takeda Pharmaceutical Co. (TAK) Altman Z-score
Takeda Pharmaceutical Co.'s Altman Z-score for fiscal 2026 is 1.03, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | 1.03 | (0.07) |
| FY2025 | 1.10 | 0.14 |
| FY2024 | 0.96 | (0.14) |
| FY2023 | 1.10 | 0.11 |
| FY2022 | 0.99 | (0.62) |
| FY2021 | 1.61 | 0.77 |
| FY2020 | 0.84 | 0.14 |
| FY2019 | 0.70 | (1.77) |
| FY2018 | 2.47 | 0.51 |
| FY2017 | 1.96 | (0.77) |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.02 | — | 0.02 | |
| Retained earnings / total assets | 0.05 | — | 0.06 | |
| EBIT / total assets | 0.00 | — | 0.00 | |
| Market value of equity / total liabilities | 1.09 | — | 0.66 | |
| Sales / total assets | 0.29 | — | 0.29 | |
| Altman Z-score | Distress zone | 1.03 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Grey zone | 1.23 | ||
Z and Z″ put Takeda Pharmaceutical Co. in different zones: distress zone by Z, grey zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| UTHR United Therapeutics Corporation compare | 19.6× |
| NBIX Neurocrine Biosciences, Inc. compare | 7.8× |
| ZTS Zoetis Inc. compare | 5.7× |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.3× |
| HLN Haleon PLC Sponsored ADR compare | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 1.3× |
| TAK Takeda Pharmaceutical Co. | 1.0× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 0.8× |
| VTRS Viatris Inc. compare | 0.6× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets